Gilead Sciences Inc

GILD.O

Official Data Partner

Latest Trade: trading higher83.95USD
Change; 0.6; 0.72%Positive

As of Jan 31 2023. Values delayed up to 15 minutes

Day Range: 83.22 - 84.21
52-Week Range: 57.16 - 89.74

Previous Close: 83.35
Open: 83.52
Volume: 9,528,300.00
3 Month Average Trading Volume: 151.94
Shares Out (Mil): 1,254.24
Market Cap: 105,017.80
Forward P/E: 11.73
Dividend Yield: 3.49

Key Statistics

2.5483871 mean rating - 31 analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): 31.66
Price To Sales (TTM): 3.87
Price To Book (Quarterly): 4.98
Price To Cash Flow (Per Share TTM): 19.38
Total Debt/Total Equity (Quarterly): 119.65
Long Term Debt/Equity (Quarterly): 108.88
Return On Investment (TTM): 6.07
Return On Equity (TTM): 5.10

2021 (millions USD)

About Gilead Sciences Inc (GILD.O)

Company Information

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.

Address

333 LAKESIDE DR
FOSTER CITY, CA
94404
United States

Contact Information

+1 (650) 5743000

https://www.gilead.com/

Industry

Biotechnology & Drugs

Executive Leadership

Daniel O'Day: Chairman of the Board, Chief Executive Officer
Andrew D. Dickinson: Chief Financial Officer
Deborah H. Telman: Executive Vice President - Corporate Affairs, General Counsel, Corporate Secretary
Stacey Ma: Executive Vice President - Pharmaceutical Development and Manufacturing
Flavius Martin: Executive Vice President - Research
Johanna Mercier: Chief Commercial Officer
Merdad V. Parsey: Chief Medical Officer
Kevin E. Lofton: Lead Independent Director
Jacqueline K. Barton: Independent Director
Jeffrey A. Bluestone: Independent Director
Sandra J. Horning: Independent Director
Kelly A. Kramer: Independent Director
Harish Manwani: Independent Director
Javier J. Rodriguez: Independent Director
Anthony Welters: Independent Director